Table 3 Univariable Cox proportional hazard analyses for survival (n = 466).
Characteristic | DRFS | OS | ||
|---|---|---|---|---|
HR (95% CI) | P value | HR (95% CI) | P value | |
Age, years: 20–50 vs. > 50 | 1.64 (1.05–2.57) | 0.03 | 2.12 (1.22–3.70) | 0.008 |
Tumor stage: T2 vs. T3–4 | 1.74 (1.13–2.68) | 0.01 | 1.94 (1.12–3.36) | 0.02 |
Clinical N stage: N0 vs. N1–3 | 4.03 (2.08–7.81) | < 0.001 | 8.56 (2.67–27.47) | < 0.001 |
Histologic grade: G1–2 vs. G3 | 1.07 (0.58–1.98) | 0.82 | 1.73 (0.89–3.38) | 0.11 |
ER score (Allred): 3–6 vs. 7–8 | 0.90 (0.49–1.65) | 0.73 | 0.75 (0.36–1.53) | 0.42 |
PR status: negative vs. positive | 0.64 (0.39–1.06) | 0.09 | 0.50 (0.28–0.91) | 0.02 |
Ki-67 expression: < 20% vs. ≥ 20% | 2.48 (1.26–4.88) | 0.009 | 4.63 (1.53–13.98) | 0.007 |
Maximum SUV: continuous | 1.08 (1.02–1.14) | 0.01 | 1.13 (1.06–1.21) | < 0.001 |
Maximum SUV: < 5.14 vs. ≥ 5.14a | 2.21 (1.40–3.48) | 0.001 | 3.70 (1.94–7.07) | < 0.001 |
Maximum SUV: Ter1 vs. Ter2 | 2.42 (1.26–4.63) | 0.008 | 2.78 (1.00–7.71) | 0.05 |
Maximum SUV: Ter1 vs. Ter3 | 3.48 (1.87–6.50) | < 0.001 | 7.19 (2.80–18.45) | < 0.001 |
